Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAPPHIRE: Real-world safety and effectiveness of canagliflozin in type 2 diabetes mellitus in Japan
jRCT1080222994Completed
- Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Start
- Oct 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of canagliflozin in type 2 diabetes mellitus (T2DM), sponsored by Mitsubishi Tanabe Pharma Corporation. Started Oct 2015; status: completed.
02
Drugs
canagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCT1080222994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080222994.